Peptide vaccination for castration-resistant prostate cancer

Since both tumor cells and host immune cell repertoires are diverse and heterogeneous, immune responses against tumor associated antigens shall be substantially different among individual patients with prostate cancer. Subsequently, selection of suitable peptide vaccines for individual patients base...

Full description

Saved in:
Bibliographic Details
Published inNihon rinshō Vol. 72; no. 12; p. 2147
Main Authors Koga, Noriko, Noguchi, Masanori
Format Journal Article
LanguageJapanese
Published Japan 01.12.2014
Subjects
Cancer Vaccines - therapeutic use
Clinical Trials, Phase III as Topic
Dendritic Cells - immunology
Humans
Male
Prostatic Neoplasms, Castration-Resistant - immunology
Prostatic Neoplasms, Castration-Resistant - therapy
Vaccination
Vaccines, Subunit - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Since both tumor cells and host immune cell repertoires are diverse and heterogeneous, immune responses against tumor associated antigens shall be substantially different among individual patients with prostate cancer. Subsequently, selection of suitable peptide vaccines for individual patients based on the pre-existing host immunity before vaccination could induce potent anti-tumor responses capable of providing clinical benefit for prostate cancer patients. We have developed a novel immunotherapeutic approach of personalized peptide vaccination (PPV) in which a maximum of four human leukocyte antigen (HLA)-class IA-matched peptides were selected for vaccination among pooled peptides based on both HLA-class IA type and the pre-existing host immunity before vaccination. We discuss our recent results of clinical studies of peptide vaccination for castration-resistant prostate cancer and the future direction of therapeutic cancer vaccines.
ISSN:0047-1852